Unmet Needs and Future Directions in the Management of CIM
July 22nd 2022Martin Dietrich, MD, PhD, and Edgardo Santos, MD, FACP, offer closing remarks on unmet needs and future directions in the management of CIM including other disease states where trilaciclib may offer myeloprotective benefit.
Read More
Trilaciclib Efficacy in the Prevention of CIM in ES-SCLC
July 15th 2022Renowned leaders in thoracic oncology discuss efficacy data from key clinical trials that led to the FDA approval of the CDK4/6 inhibitor trilaciclib for CIM prophylaxis in ES-SCLC, including the drug’s role in later treatment lines.
Read More
Dr. Dietrich on Optimal Adverse Event Management for Neratinib in Breast Cancer
August 16th 2019Martin Dietrich, MD, PhD, medical oncologist, Advent Health Cancer Institute, discusses management of diarrhea, an associated adverse event of neratinib, following data from the CONTROL trial in patients with HER2-positive breast cancer.
Read More